Patent ID: 11891426
Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A CD19 variant having at least 99% sequence identity to SEQ ID NO:2 wherein,
the CD19 variant comprises amino acid substitutions at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2 selected from the following:
S/V/S; G/V/R; S/R/R; T/V/P; S/R/S; E/R/P; E/W/R; E/V/V; D/L/P; A/R/L; W/S/S; T/R/Q; R/V/R; E/E/V; Y/S/R; D/V/M; W/V/A; TN/F; R/A/F; E/C/S; E/R/R; D/V/R; S/V/A; T/A/S; H/F/R; T/V/R; T/M/S; S/V/R; H/V/S; S/F/N; N/L/P; D/V/S; W/T/A; D/A/S; G/V/K wherein the CD19 variant has improved binding to an anti-CD19 antibody relative to a polypeptide comprising the amino acid sequence of SEQ ID NO:2; or
the CD19 variant comprises amino acid substitutions at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2 selected from the following:
Y/S/T; V/G/D; A/Q/T; V/E/E; wherein the CD19 variant is more resistant to protease cleavage relative to a polypeptide comprising the amino acid sequence of SEQ ID NO:2.